AKBA

false2022FY0001517022http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent5P1Y0.33330.33330.3333P1YP2YP3YP1Y0.3333P1Y0.6667P2Yhttp://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent00015170222022-01-012022-12-3100015170222022-06-30iso4217:USD00015170222023-02-28xbrli:shares00015170222022-12-3100015170222021-12-31iso4217:USDxbrli:shares0001517022us-gaap:ProductMember2022-01-012022-12-310001517022us-gaap:ProductMember2021-01-012021-12-310001517022us-gaap:ProductMember2020-01-012020-12-310001517022akba:LicenseCollaborationAndOtherRevenueMember2022-01-012022-12-310001517022akba:LicenseCollaborationAndOtherRevenueMember2021-01-012021-12-310001517022akba:LicenseCollaborationAndOtherRevenueMember2020-01-012020-12-3100015170222021-01-012021-12-3100015170222020-01-012020-12-310001517022us-gaap:CommonStockMember2019-12-310001517022us-gaap:AdditionalPaidInCapitalMember2019-12-310001517022us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310001517022us-gaap:RetainedEarningsMember2019-12-3100015170222019-12-310001517022us-gaap:CommonStockMember2020-01-012020-12-310001517022us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001517022us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-12-310001517022us-gaap:RetainedEarningsMember2020-01-012020-12-310001517022us-gaap:CommonStockMember2020-12-310001517022us-gaap:AdditionalPaidInCapitalMember2020-12-310001517022us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310001517022us-gaap:RetainedEarningsMember2020-12-3100015170222020-12-310001517022us-gaap:CommonStockMember2021-01-012021-12-310001517022us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001517022us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-12-310001517022us-gaap:RetainedEarningsMember2021-01-012021-12-310001517022us-gaap:CommonStockMember2021-12-310001517022us-gaap:AdditionalPaidInCapitalMember2021-12-310001517022us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001517022us-gaap:RetainedEarningsMember2021-12-310001517022us-gaap:CommonStockMember2022-01-012022-12-310001517022us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001517022us-gaap:RetainedEarningsMember2022-01-012022-12-310001517022us-gaap:CommonStockMember2022-12-310001517022us-gaap:AdditionalPaidInCapitalMember2022-12-310001517022us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001517022us-gaap:RetainedEarningsMember2022-12-31akba:commercial_product0001517022akba:BioVectraIncMember2022-12-220001517022akba:BioVectraIncMember2022-12-222022-12-22akba:quarter_period0001517022akba:RestructuringPlanNovember2022Member2022-11-012022-11-30xbrli:pureakba:segment0001517022us-gaap:CustomerConcentrationRiskMemberakba:FreseniusMedicalCareRxMemberakba:SalesAndCollaborationRevenueGrossMember2022-01-012022-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:FreseniusMedicalCareRxMemberakba:SalesAndCollaborationRevenueGrossMember2021-01-012021-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:FreseniusMedicalCareRxMemberakba:SalesAndCollaborationRevenueGrossMember2020-01-012020-12-310001517022akba:OtsukaPharmaceuticalCompanyLimitedMemberus-gaap:CustomerConcentrationRiskMemberakba:SalesAndCollaborationRevenueGrossMember2022-01-012022-12-310001517022akba:OtsukaPharmaceuticalCompanyLimitedMemberus-gaap:CustomerConcentrationRiskMemberakba:SalesAndCollaborationRevenueGrossMember2021-01-012021-12-310001517022akba:OtsukaPharmaceuticalCompanyLimitedMemberus-gaap:CustomerConcentrationRiskMemberakba:SalesAndCollaborationRevenueGrossMember2020-01-012020-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:AmerisourceBergenDrugCorporationMemberakba:SalesAndCollaborationRevenueGrossMember2022-01-012022-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:AmerisourceBergenDrugCorporationMemberakba:SalesAndCollaborationRevenueGrossMember2021-01-012021-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:AmerisourceBergenDrugCorporationMemberakba:SalesAndCollaborationRevenueGrossMember2020-01-012020-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:McKessonCorporationMemberakba:SalesAndCollaborationRevenueGrossMember2022-01-012022-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:McKessonCorporationMemberakba:SalesAndCollaborationRevenueGrossMember2021-01-012021-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:McKessonCorporationMemberakba:SalesAndCollaborationRevenueGrossMember2020-01-012020-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:CardinalHealthIncMemberakba:SalesAndCollaborationRevenueGrossMember2022-01-012022-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:CardinalHealthIncMemberakba:SalesAndCollaborationRevenueGrossMember2021-01-012021-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:CardinalHealthIncMemberakba:SalesAndCollaborationRevenueGrossMember2020-01-012020-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:FreseniusMedicalCareRxMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:FreseniusMedicalCareRxMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:AmerisourceBergenDrugCorporationMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:AmerisourceBergenDrugCorporationMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:CardinalHealthIncMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001517022us-gaap:CustomerConcentrationRiskMemberakba:CardinalHealthIncMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001517022us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberakba:McKessonCorporationMember2022-01-012022-12-310001517022us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberakba:McKessonCorporationMember2021-01-012021-12-310001517022akba:OtsukaPharmaceuticalCompanyLimitedMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001517022akba:OtsukaPharmaceuticalCompanyLimitedMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001517022us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberakba:MitsubishiTanabePharmaCorporationMember2022-01-012022-12-310001517022us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberakba:MitsubishiTanabePharmaCorporationMember2021-01-012021-12-310001517022srt:MinimumMember2022-01-012022-12-310001517022srt:MaximumMember2022-01-012022-12-310001517022akba:ComputerEquipmentAndSoftwareMember2022-01-012022-12-310001517022akba:ComputerEquipmentAndSoftwareMember2022-12-310001517022akba:ComputerEquipmentAndSoftwareMember2021-12-310001517022us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2022-01-012022-12-310001517022us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2022-01-012022-12-310001517022us-gaap:FurnitureAndFixturesMember2022-12-310001517022us-gaap:FurnitureAndFixturesMember2021-12-310001517022us-gaap:EquipmentMember2022-01-012022-12-310001517022us-gaap:EquipmentMember2022-12-310001517022us-gaap:EquipmentMember2021-12-310001517022us-gaap:LeaseholdImprovementsMember2022-12-310001517022us-gaap:LeaseholdImprovementsMember2021-12-3100015170222022-10-012022-12-3100015170222020-04-012020-06-300001517022us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001517022us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310001517022us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001517022akba:ChargebacksAndDiscountsMember2019-12-310001517022akba:RebatesFeesAndOtherDeductionsMember2019-12-310001517022akba:ReturnsMember2019-12-310001517022akba:ChargebacksAndDiscountsMember2020-01-012020-12-310001517022akba:RebatesFeesAndOtherDeductionsMember2020-01-012020-12-310001517022akba:ReturnsMember2020-01-012020-12-310001517022akba:ChargebacksAndDiscountsMember2020-12-310001517022akba:RebatesFeesAndOtherDeductionsMember2020-12-310001517022akba:ReturnsMember2020-12-310001517022akba:ChargebacksAndDiscountsMember2021-01-012021-12-310001517022akba:RebatesFeesAndOtherDeductionsMember2021-01-012021-12-310001517022akba:ReturnsMember2021-01-012021-12-310001517022akba:ChargebacksAndDiscountsMember2021-12-310001517022akba:RebatesFeesAndOtherDeductionsMember2021-12-310001517022akba:ReturnsMember2021-12-310001517022akba:ChargebacksAndDiscountsMember2022-01-012022-12-310001517022akba:RebatesFeesAndOtherDeductionsMember2022-01-012022-12-310001517022akba:ReturnsMember2022-01-012022-12-310001517022akba:ChargebacksAndDiscountsMember2022-12-310001517022akba:RebatesFeesAndOtherDeductionsMember2022-12-310001517022akba:ReturnsMember2022-12-310001517022us-gaap:ProductMember2022-12-310001517022us-gaap:ProductMember2021-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationMember2022-01-012022-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationMember2021-01-012021-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationMember2020-01-012020-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2021-01-012021-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2020-01-012020-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2021-01-012021-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2020-01-012020-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2021-01-012021-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2020-01-012020-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2021-01-012021-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2020-01-012020-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationMemberus-gaap:OtherIncomeMember2022-01-012022-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationMemberus-gaap:OtherIncomeMember2021-01-012021-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationMemberus-gaap:OtherIncomeMember2020-01-012020-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeCollaborationAgreementMember2022-12-310001517022akba:ViforPharmaMember2022-12-310001517022us-gaap:AccountsReceivableMember2021-12-310001517022us-gaap:AccountsReceivableMember2022-01-012022-12-310001517022us-gaap:AccountsReceivableMember2022-12-310001517022us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310001517022us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-01-012022-12-310001517022us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310001517022akba:DeferredRevenueMember2021-12-310001517022akba:DeferredRevenueMember2022-01-012022-12-310001517022akba:DeferredRevenueMember2022-12-310001517022us-gaap:AccountsPayableMember2021-12-310001517022us-gaap:AccountsPayableMember2022-01-012022-12-310001517022us-gaap:AccountsPayableMember2022-12-310001517022us-gaap:AccountsReceivableMember2020-12-310001517022us-gaap:AccountsReceivableMember2021-01-012021-12-310001517022us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-12-310001517022us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-01-012021-12-310001517022akba:DeferredRevenueMember2020-12-310001517022akba:DeferredRevenueMember2021-01-012021-12-310001517022us-gaap:AccountsPayableMember2020-12-310001517022us-gaap:AccountsPayableMember2021-01-012021-12-310001517022akba:AccruedExpensesAndOtherCurrentLiabilitiesMember2020-12-310001517022akba:AccruedExpensesAndOtherCurrentLiabilitiesMember2021-01-012021-12-310001517022akba:AccruedExpensesAndOtherCurrentLiabilitiesMember2021-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationCollaborationAgreementGlobalPhase3ProgramMember2015-12-112015-12-110001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeCollaborationAgreementMemberakba:RegulatoryMilestonePaymentsMember2020-07-012020-09-300001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeCollaborationAgreementMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeCollaborationAgreementMemberakba:DevelopmentRegulatoryAndCommercialEventsMilestonesPaymentMembersrt:MaximumMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentMilestonesPaymentMemberakba:DevelopmentAndCommercializeCollaborationAgreementMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeCollaborationAgreementMembersrt:MaximumMemberakba:RegulatoryMilestonePaymentsMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:RegulatoryMilestonePaymentsMember2019-07-012019-09-300001517022akba:CommercialMilestonePaymentsMemberakba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeCollaborationAgreementMembersrt:MaximumMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMembersrt:MinimumMemberakba:DevelopmentAndCommercializeCollaborationAgreementMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeCollaborationAgreementMembersrt:MaximumMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeCollaborationAgreementMemberakba:RegulatoryMilestonePaymentsMember2022-01-012022-12-31akba:performance_obligation0001517022akba:MitsubishiTanabePharmaCorporationMember2020-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:RegulatoryMilestonePaymentsMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:RegulatoryMilestoneApprovalOfVadadustatInJapanMember2020-01-012020-12-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:MitsubishiTanabePharmaCorporationMember2019-01-012019-12-310001517022akba:MitsubishiTanabePharmaCorporationMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMember2021-01-012021-12-310001517022akba:MitsubishiTanabePharmaCorporationMember2020-01-012020-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberus-gaap:AccountsReceivableMemberakba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember2022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember2022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2020-04-012020-06-300001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2021-01-012021-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2020-01-012020-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberus-gaap:AccountsReceivableMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberus-gaap:OtherCurrentLiabilitiesMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberus-gaap:OtherNoncurrentLiabilitiesMemberakba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember2022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationSupplyAgreementMember2022-01-012022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationSupplyAgreementMember2021-01-012021-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationSupplyAgreementMember2020-01-012020-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberus-gaap:AccountsReceivableMemberakba:MitsubishiTanabePharmaCorporationSupplyAgreementMember2022-12-310001517022akba:MitsubishiTanabePharmaCorporationMemberakba:MitsubishiTanabePharmaCorporationSupplyAgreementMember2022-12-310001517022akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2019-03-310001517022akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2019-04-010001517022akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:UpFrontNonRefundableAndNonCreditableMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2016-12-182016-12-310001517022akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2022-07-012022-07-310001517022akba:LicenseCollaborationAndOtherRevenueMemberakba:DevelopmentAndCommercializeUnitedStatesAndInternationalCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2021-01-012021-12-310001517022akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2020-01-012020-12-310001517022akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMemberakba:UpFrontNonRefundableAndNonCreditableMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2017-04-012022-12-310001517022us-gaap:AccountsPayableMemberakba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2021-12-310001517022akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberakba:OtsukaPharmaceuticalCompanyLimitedMember2021-12-310001517022akba:JanssenPharmaceuticaNVMemberakba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember2017-02-090001517022akba:CyclerionTherapeuticsLicenseAgreementMember2021-06-042021-06-040001517022akba:CyclerionTherapeuticsLicenseAgreementMember2021-06-012021-06-300001517022akba:ViforInternationalLimitedMemberus-gaap:LicenseMember2022-02-180001517022akba:LicenseAgreementMemberakba:ViforInternationalLimitedMember2019-04-082019-04-080001517022akba:ViforInternationalLimitedMember2022-02-182022-02-180001517022akba:ViforInternationalLimitedMember2022-01-012022-12-310001517022akba:LicenseAgreementMemberakba:ViforInternationalLimitedMember2017-05-310001517022akba:LicenseAgreementMemberakba:ViforInternationalLimitedMember2017-05-012017-05-310001517022us-gaap:PrivatePlacementMember2022-02-222022-02-220001517022akba:ViforInternationalLimitedMemberus-gaap:LicenseMember2022-01-012022-12-310001517022akba:LicenseAgreementMemberakba:ViforInternationalLimitedMember2017-05-120001517022akba:ViforInternationalLimitedMember2022-12-310001517022akba:ViforInternationalLimitedMemberus-gaap:LicenseMember2022-12-310001517022akba:ViforInternationalLimitedMemberakba:PriorityReviewVoucherLetterAgreementMember2020-02-142020-02-140001517022akba:ViforInternationalLimitedMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001517022akba:ViforInternationalLimitedMemberakba:PriorityReviewVoucherLetterAgreementMember2021-10-012021-12-310001517022akba:LicenseAgreementMemberakba:PanionAndBFBiotechIncorporationMemberakba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2019-04-172019-04-170001517022akba:LicenseAgreementMemberakba:PanionAndBFBiotechIncorporationMemberakba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2022-01-012022-12-310001517022akba:LicenseAgreementMemberakba:PanionAndBFBiotechIncorporationMemberakba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2021-01-012021-12-310001517022akba:LicenseAgreementMemberakba:PanionAndBFBiotechIncorporationMemberakba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2020-01-012020-12-310001517022akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMemberakba:SublicenseAgreementMember2022-01-012022-12-310001517022akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMemberakba:SublicenseAgreementMember2021-01-012021-12-310001517022akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMemberakba:SublicenseAgreementMember2020-01-012020-12-310001517022akba:AveroaSASMemberus-gaap:LicenseMember2022-12-222022-12-220001517022akba:AveroaSASMember2022-12-222022-12-220001517022akba:RestructuringPlanApril2022Member2022-04-040001517022akba:RestructuringPlanApril2022Member2022-01-012022-12-310001517022akba:RestructuringPlanNovember2022Member2022-11-072022-11-070001517022akba:RestructuringPlanNovember2022Member2022-01-012022-12-3100015170222021-02-2500015170222021-02-252021-02-250001517022us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001517022us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001517022us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001517022us-gaap:FairValueMeasurementsRecurringMember2022-12-310001517022us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001517022us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001517022us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001517022us-gaap:FairValueMeasurementsRecurringMember2021-12-310001517022akba:CollateralAgentPharmakonMember2022-12-310001517022akba:CollateralAgentPharmakonMember2021-12-310001517022akba:MeasurementInputClinicalDevelopmentSuccessMemberus-gaap:FairValueInputsLevel3Memberakba:ValuationTechniqueScenarioBasedAndDiscountedCashFlowMember2022-12-310001517022akba:MeasurementInputClinicalDevelopmentSuccessMemberus-gaap:FairValueInputsLevel3Memberakba:ValuationTechniqueScenarioBasedAndDiscountedCashFlowMember2021-12-310001517022us-gaap:FairValueInputsLevel3Memberakba:OtherThanDerivativeLiabilitiesMember2022-12-310001517022us-gaap:FairValueInputsLevel3Memberakba:OtherThanDerivativeLiabilitiesMember2021-12-310001517022us-gaap:FairValueInputsLevel3Member2022-12-310001517022us-gaap:FairValueInputsLevel3Member2021-12-310001517022akba:KeryxBiopharmaceuticalsIncMember2022-01-012022-12-310001517022akba:KeryxBiopharmaceuticalsIncMember2021-01-012021-12-310001517022akba:KeryxBiopharmaceuticalsIncMember2020-01-012020-12-310001517022akba:DevelopedProductRightsForAuryxiaMember2022-12-310001517022akba:DevelopedProductRightsForAuryxiaMember2021-12-310001517022akba:DevelopedProductRightsForAuryxiaMember2022-01-012022-12-310001517022akba:DevelopedProductRightsForAuryxiaMember2021-01-012021-12-310001517022akba:DevelopedProductRightsForAuryxiaMember2020-01-012020-12-310001517022us-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2022-12-310001517022akba:DevelopedProductRightsForAuryxiaMember2021-01-012021-03-310001517022akba:DevelopedProductRightsForAuryxiaMember2020-04-012020-09-300001517022akba:DevelopedProductRightsForAuryxiaMember2020-10-012020-12-310001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:KeryxMemberakba:CollateralAgentPharmakonMember2019-11-11akba:tranche0001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:KeryxMemberakba:CollateralAgentPharmakonMemberakba:TrancheAMember2019-11-110001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:TrancheBMemberakba:KeryxMemberakba:CollateralAgentPharmakonMember2019-11-110001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:KeryxMemberakba:CollateralAgentPharmakonMemberakba:ThreeMonthLondonInterbankOfferedRateMember2019-11-112019-11-110001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberus-gaap:LondonInterbankOfferedRateLIBORMemberakba:KeryxMemberakba:CollateralAgentPharmakonMember2019-11-112019-11-110001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMemberakba:KeryxMemberakba:CollateralAgentPharmakonMember2019-11-112019-11-110001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:KeryxMemberakba:CollateralAgentPharmakonMemberakba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember2019-11-112019-11-110001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:KeryxMemberakba:CollateralAgentPharmakonMember2022-01-012022-12-310001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:KeryxMemberakba:CollateralAgentPharmakonMember2019-11-112019-11-110001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:KeryxMemberakba:CollateralAgentPharmakonMemberakba:TrancheAMember2019-11-250001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:TrancheBMemberakba:KeryxMemberakba:CollateralAgentPharmakonMember2020-12-102020-12-100001517022akba:TermLoanMemberakba:CollateralAgentPharmakonMemberakba:TrancheAMember2022-07-152022-07-150001517022akba:TermLoanMemberakba:TrancheBMemberakba:CollateralAgentPharmakonMember2022-07-152022-07-150001517022akba:TermLoanMemberakba:CollateralAgentPharmakonMemberakba:TrancheAAndBMember2022-07-152022-07-150001517022akba:TermLoanMemberakba:CollateralAgentPharmakonMemberakba:TrancheAAndBMember2022-01-012022-12-310001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:KeryxMemberakba:CollateralAgentPharmakonMember2021-01-012021-12-310001517022akba:TermLoanMemberakba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMemberakba:KeryxMemberakba:CollateralAgentPharmakonMember2020-01-012020-12-3100015170222020-06-0400015170222020-06-050001517022akba:AtTheMarketEquityOfferingProgramMembersrt:MaximumMember2020-03-122020-03-120001517022us-gaap:CommonStockMemberakba:AtTheMarketEquityOfferingProgramMember2021-01-012021-12-310001517022us-gaap:CommonStockMemberakba:AtTheMarketEquityOfferingProgramMember2020-01-012020-12-310001517022us-gaap:CommonStockMemberakba:AtTheMarketEquityOfferingProgramMember2021-01-012021-03-310001517022us-gaap:CommonStockMemberakba:AtTheMarketEquityOfferingProgramMember2022-01-012022-03-310001517022akba:AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Membersrt:MaximumMember2021-02-252021-02-250001517022us-gaap:CommonStockMemberakba:AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member2021-01-012021-12-310001517022akba:AtTheMarketEquityOfferingProgramAuthorizedMarch2022Membersrt:MaximumMember2022-03-012022-03-010001517022us-gaap:CommonStockMemberakba:AtTheMarketEquityOfferingProgramAuthorizedMarch2022Member2022-01-012022-03-310001517022akba:OpenMarketSaleAgreementAuthorizedApril2022Membersrt:MaximumMember2022-04-072022-04-07akba:stock_incentive_plan0001517022akba:InducementAwardProgramMember2022-01-012022-12-310001517022akba:InducementAwardProgramMember2022-12-310001517022akba:TwoThousandAndFourteenPlansMember2014-02-280001517022akba:TwoThousandAndFourteenPlansMember2022-01-012022-12-310001517022us-gaap:EmployeeStockOptionMemberakba:EmployeesMemberakba:TwoThousandAndFourteenPlansMember2022-01-012022-12-310001517022akba:EmployeesMemberakba:InducementAwardProgramMember2022-01-012022-12-310001517022akba:EmployeesMemberus-gaap:RestrictedStockUnitsRSUMemberakba:TwoThousandAndFourteenPlansMember2022-01-012022-12-310001517022akba:PerformanceBasedRestrictedStockUnitMemberakba:EmployeesMemberakba:TwoThousandAndFourteenPlansMember2022-01-012022-12-310001517022srt:DirectorMemberus-gaap:EmployeeStockOptionMemberakba:TwoThousandAndFourteenPlansMember2022-01-012022-12-310001517022srt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMemberakba:TwoThousandAndFourteenPlansMember2022-01-012022-12-310001517022akba:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2022-12-310001517022akba:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2022-01-012022-12-310001517022akba:OptionRestrictedStockUnitsRSUsAndPerformanceBasedRestrictedStockUnitsPSUsMember2022-12-310001517022akba:OptionRestrictedStockUnitsRSUsAndPerformanceBasedRestrictedStockUnitsPSUsMember2021-12-310001517022akba:AkebiaEquityPlansMember2022-12-310001517022akba:AkebiaEquityPlansMember2021-12-310001517022us-gaap:WarrantMember2022-12-310001517022us-gaap:WarrantMember2021-12-310001517022us-gaap:EmployeeStockMember2022-12-310001517022us-gaap:EmployeeStockMember2021-12-310001517022akba:TwoThousandAndFourteenPlansMember2022-01-012022-01-010001517022akba:TwoThousandAndFourteenPlansMember2021-01-012021-01-010001517022akba:TwoThousandAndFourteenPlansMember2020-01-012020-01-010001517022us-gaap:EmployeeStockOptionMember2021-02-282021-02-280001517022us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-12-310001517022us-gaap:EmployeeStockOptionMembersrt:MaximumMember2022-01-012022-12-310001517022us-gaap:EmployeeStockOptionMemberakba:ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember2022-01-012022-12-310001517022us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001517022us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-01-012022-12-31akba:installment0001517022us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001517022us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001517022us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001517022akba:TwoThousandAndFourteenPlansMember2021-01-012021-12-310001517022akba:TwoThousandAndFourteenPlansMember2020-01-012020-12-310001517022srt:MinimumMemberakba:TwoThousandAndFourteenPlansMember2022-01-012022-12-310001517022srt:MaximumMemberakba:TwoThousandAndFourteenPlansMember2022-01-012022-12-310001517022srt:MinimumMemberakba:TwoThousandAndFourteenPlansMember2021-01-012021-12-310001517022srt:MaximumMemberakba:TwoThousandAndFourteenPlansMember2021-01-012021-12-310001517022srt:MinimumMemberakba:TwoThousandAndFourteenPlansMember2020-01-012020-12-310001517022srt:MaximumMemberakba:TwoThousandAndFourteenPlansMember2020-01-012020-12-310001517022us-gaap:EmployeeStockOptionMember2021-12-310001517022us-gaap:EmployeeStockOptionMember2022-12-310001517022akba:InducementAwardProgramMemberakba:TwoThousandAndFourteenPlansMember2022-12-310001517022akba:InducementAwardProgramMemberakba:TwoThousandAndFourteenPlansMember2022-01-012022-12-310001517022akba:PerformanceBasedStockOptionsMember2022-01-012022-12-310001517022akba:PerformanceBasedStockOptionsMember2021-01-012021-12-310001517022akba:PerformanceBasedStockOptionsMember2022-12-310001517022akba:PerformanceBasedStockOptionsMember2021-12-310001517022akba:PerformanceBasedStockOptionsMember2020-01-012020-12-310001517022akba:PerformanceBasedStockOptionsMemberakba:TwoThousandAndFourteenPlansMember2022-12-310001517022us-gaap:RestrictedStockUnitsRSUMember2021-02-282021-02-280001517022akba:ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMemberakba:ServiceBasedRestrictedStockUnitsMember2022-01-012022-12-310001517022us-gaap:ShareBasedCompensationAwardTrancheOneMemberakba:ServiceBasedRestrictedStockUnitsMember2022-01-012022-12-310001517022us-gaap:ShareBasedCompensationAwardTrancheTwoMemberakba:ServiceBasedRestrictedStockUnitsMember2022-01-012022-12-310001517022akba:ShareBasedPaymentArrangementTrancheTwoFollowingFirstAnniversaryAfterGrantDateMemberakba:ServiceBasedRestrictedStockUnitsMember2022-01-012022-12-310001517022akba:EmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001517022akba:EmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001517022akba:EmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001517022akba:PerformanceBasedRestrictedStockUnitMember2022-01-012022-12-310001517022akba:PerformanceBasedRestrictedStockUnitMember2021-01-012021-12-310001517022akba:PerformanceBasedRestrictedStockUnitMember2020-01-012020-12-310001517022akba:RestrictedStockUnitsRSUsAndPerformanceBasedRestrictedStockUnitsPSUsMember2021-12-310001517022akba:RestrictedStockUnitsRSUsAndPerformanceBasedRestrictedStockUnitsPSUsMember2022-01-012022-12-310001517022akba:RestrictedStockUnitsRSUsAndPerformanceBasedRestrictedStockUnitsPSUsMember2022-12-310001517022akba:RestrictedStockUnitsRSUsAndPerformanceBasedRestrictedStockUnitsPSUsMember2021-01-012021-12-310001517022akba:RestrictedStockUnitsRSUsAndPerformanceBasedRestrictedStockUnitsPSUsMember2020-01-012020-12-310001517022akba:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2021-01-012021-12-310001517022akba:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2020-01-012020-12-310001517022us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001517022us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001517022us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001517022us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001517022us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001517022us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001517022srt:MinimumMemberakba:ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMemberakba:ServiceBasedRestrictedStockUnitsMember2022-01-012022-12-310001517022us-gaap:RestrictedStockUnitsRSUMemberakba:ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember2022-01-012022-12-310001517022akba:ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001517022us-gaap:RestrictedStockUnitsRSUMemberakba:ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember2022-01-012022-12-310001517022us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001517022akba:ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateMemberakba:ServiceBasedRestrictedStockUnitsMember2022-01-012022-12-310001517022us-gaap:DomesticCountryMember2022-12-310001517022us-gaap:DomesticCountryMember2021-12-310001517022us-gaap:StateAndLocalJurisdictionMember2022-12-310001517022us-gaap:StateAndLocalJurisdictionMember2021-12-31akba:age0001517022akba:CambridgeMember2020-11-30utr:sqft0001517022akba:CambridgeMember2016-07-012016-07-310001517022akba:CambridgeMember2017-01-012017-01-010001517022akba:CambridgeMemberakba:OfficeSpaceMember2018-04-300001517022akba:CambridgeMember2016-07-310001517022akba:CambridgeMemberakba:OfficeSpaceMember2019-02-012019-02-280001517022akba:CambridgeMemberakba:OfficeSpaceMember2020-12-012020-12-310001517022akba:CambridgeMemberakba:OfficeSpaceMember2021-12-012021-12-310001517022akba:BostonMemberakba:OfficeSpaceMember2022-12-310001517022akba:BostonMemberakba:OfficeSpaceMember2022-01-012022-12-310001517022akba:BostonMemberakba:OfficeSpaceMember2022-02-012022-02-280001517022akba:BostonMemberakba:OfficeSpaceMember2022-02-280001517022akba:CambridgeMemberakba:OfficeSpaceMember2022-12-31akba:extensionOption0001517022akba:BostonMemberakba:KeryxBiopharmaceuticalsIncMemberakba:OfficeSpaceMember2022-12-310001517022akba:CambridgeMemberakba:LabSpaceMember2022-12-310001517022akba:BostonMemberakba:KeryxBiopharmaceuticalsIncMemberakba:OfficeSpaceMember2020-01-012020-12-310001517022akba:BostonMemberakba:KeryxBiopharmaceuticalsIncMemberakba:OfficeSpaceMember2022-01-012022-12-310001517022akba:BostonMemberakba:KeryxBiopharmaceuticalsIncMemberakba:OfficeSpaceMember2021-01-012021-12-310001517022us-gaap:LetterOfCreditMemberakba:CambridgeMemberus-gaap:OtherCurrentAssetsMember2022-12-310001517022us-gaap:LetterOfCreditMemberakba:KeryxBiopharmaceuticalsIncMemberus-gaap:OtherCurrentAssetsMember2022-12-310001517022srt:MinimumMember2022-12-310001517022srt:MaximumMember2022-12-310001517022akba:BioVectraIncMember2022-10-012022-12-310001517022akba:SiegfriedEvionnazSAMember2022-12-310001517022akba:KeryxBiopharmaceuticalsIncMember2022-12-310001517022akba:KeryxBiopharmaceuticalsIncMember2021-12-310001517022akba:SupplyAgreementPatheonIncMember2022-01-012022-12-310001517022akba:SupplyAgreementPatheonIncMember2022-12-310001517022akba:STAPharmaceuticalHongKongLimitedMember2020-04-022020-04-020001517022akba:STAPharmaceuticalHongKongLimitedMember2022-01-012022-12-310001517022akba:WuXiSTAMember2021-02-102021-02-100001517022us-gaap:WarrantMember2022-01-012022-12-310001517022us-gaap:WarrantMember2021-01-012021-12-310001517022us-gaap:WarrantMember2020-01-012020-12-310001517022us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001517022us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001517022us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001517022us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001517022us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001517022us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001517022us-gaap:SubsequentEventMemberakba:SiegfriedEvionnazSAMember2023-02-282023-02-28

☒			ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Delaware

20-8756903

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

245 First Street, Cambridge, MA

02142

(Address of principal executive offices)

(Zip Code)

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.00001 per share			AKBA			The Nasdaq Capital Market

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐ No  ☒   

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐ No  ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒ No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒ No  ☐

Large accelerated filer			☐			Accelerated filer			☒
Non-accelerated filer			☐			Smaller reporting company			☐
						Emerging growth company			☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐ Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A in connection with its 2023 Annual Meeting of Stockholders within 120 days after the end of the registrant’s fiscal year ended December 31, 2022. Portions of the proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.

									Page No.
PART I									6
Item 1.						Business			6
Item 1A.						Risk Factors			47
Item 1B.						Unresolved Staff Comments			97
Item 2.						Properties			97
Item 3.						Legal Proceedings			97
Item 4.						Mine Safety Disclosures			99
PART II									100
Item 5.						Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities			100
Item 6.						[Reserved]			101
Item 7.						Management’s Discussion and Analysis of Financial Condition and Results of Operations			101
Item 7A.						Quantitative and Qualitative Disclosures About Market Risk			117
Item 8.						Financial Statements and Supplementary Data			119
Item 9.						Changes in and Disagreements with Accountants on Accounting and Financial Disclosure			169
Item 9A.						Controls and Procedures			169
Item 9B.						Other Information			171
Item 9C.						Disclosure Regarding Foreign Jurisdictions that Prevent Inspections			171
PART III									171
Item 10.						Directors, Executive Officers and Corporate Governance			171
Item 11.						Executive Compensation			171
Item 12.						Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters			171
Item 13.						Certain Relationships and Related Transactions, and Director Independence			172
Item 14.						Principal Accountant Fees and Services			172
PART IV									173
Item 15.						Exhibits and Financial Statement Schedules			173
Item 16.						Form 10-K Summary			180
SIGNATURES									181

•the potential therapeutic benefits, safety profile, and effectiveness of vadadustat; 

•our expectations with respect to the development of vadadustat, if any, following our receipt of a complete response letter to our new drug application for vadadustat for the treatment of anemia due to chronic kidney disease in adult patients, including the timing of a potential response to the Formal Dispute Resolution Request from the U.S. Food and Drug Administration;

•that delivering value broadly to the kidney community, as well as others who may benefit from our medicines, will result in delivering value for stockholders;

•our pipeline and portfolio, including its potential, and our related research and development activities;

•the timing of or likelihood of regulatory filings and approvals, including with respect to labeling or other restrictions, the potential approval of vadadustat and our outlook related thereto, and potential indications for vadadustat;

•the timing, investment and associated activities involved in continued commercialization of Auryxia® (ferric citrate), its growth opportunities and our ability to execute thereon;

•the potential indications, demand and market opportunity, potential and acceptance of Auryxia and vadadustat, if approved, including the size of eligible patient populations; 

•the potential therapeutic applications of the hypoxia inducible factor pathway;

•our competitive position, including estimates, developments and projections relating to our competitors and their products and product candidates, and our industry; 

•our expectations, projections and estimates regarding our capital requirements, need for additional capital, financing our future cash needs, costs, expenses, revenues, capital resources, cash flows, financial performance, profitability, tax obligations, liquidity, growth, contractual obligations, the period of time our cash resources and collaboration funding will fund our current operating plan, estimates with respect to our ability to operate as a going concern, our internal control over financial reporting and disclosure controls and procedures, and any future deficiencies or material weaknesses in our internal controls and procedures; 

•the direct or indirect impacts of the COVID-19 pandemic on our business, operations and the markets and communities in which we and our partners, collaborators, vendors, and customers operate;

•estimates, beliefs and judgments related to the valuation of intangible assets, goodwill, debt and other assets and liabilities, including our impairment analysis and our methodology and assumptions regarding fair value measurements;

•the timing of the availability and disclosure of clinical trial data and results;

•our and our collaborators’ strategy, plans and expectations with respect to the development, manufacturing, supply, commercialization, launch, marketing and sale of Auryxia and vadadustat, if approved, and the associated timing thereof; 

•the designs of our studies, and the type of information and data expected from our studies and the expected benefits thereof;

•our ability to maintain any marketing authorizations we currently hold or will obtain, including our marketing authorizations for Auryxia and our ability to complete post-marketing requirements with respect thereto;

•our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for Auryxia and vadadustat, if approved;

•the timing of initiation of our clinical trials and plans to conduct preclinical studies and clinical trials in the future; 

•the timing and amounts of payments from or to our collaborators and licensees, and the anticipated arrangements and benefits under our collaboration and license agreements, including with respect to milestones and royalties; 

•our intellectual property position, including obtaining and maintaining patents, and the timing, outcome and impact of administrative, regulatory, legal and other proceedings relating to our patents and other proprietary and intellectual property rights, patent infringement suits that we have filed or may file, or other actions that we may take against companies, and the timing and resolution thereof;

•expected ongoing reliance on third parties, including with respect to the development, manufacturing, supply and commercialization of Auryxia and vadadustat, if approved;

•accounting standards and estimates, their impact, and their expected timing of completion;

•estimated periods of performance of key contracts;

•our facilities, lease commitments, and future availability of facilities;

•cybersecurity;

•insurance coverage;

•management of personnel, including our management team, and our employees, including employee compensation, employee relations, and our ability to attract, train and retain high quality employees;

•the implementation of our business model, current operating plan, and strategic plans for our business, product candidates and technology, and business development opportunities including potential collaborations, alliances, mergers, acquisitions or licensing of assets;

•our workforce reductions, future charges expected to be incurred in connection therewith and estimated reductions in net cash required for operating activities in connection therewith; and

•the timing, outcome and impact of current and any future legal proceedings.

AURYXIA®, AKEBIA Therapeutics®, VafseoTM and their associated logos are trademarks of Akebia and/or its affiliates. All other trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners. All website addresses given in this Annual Report on Form 10-K are for information only and are not intended to be an active link or to incorporate any website information into this document.

•We may not be successful in our efforts to identify, acquire, in-license, discover, develop and commercialize additional products or product candidates or our decisions to prioritize the development of certain product candidates over others may not be successful, which could impair our ability to grow.

•The commercialization of RionaTM and VafseoTM in Japan and our current and potential future efforts with respect to the development and commercialization of our products and product candidates outside of the United States subject us to a variety of risks associated with international operations, which could materially adversely affect our business.

•Litigation and administrative proceedings, including third party claims of intellectual property infringement and opposition/invalidation proceedings against third party patents, may be costly and time consuming and may delay or harm our drug discovery, development and commercialization efforts.

•Our stock price has been and may continue to be volatile, which could result in substantial losses for holders or future purchasers of our common stock and lawsuits against us and our officers and directors.

•Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, or HIF-PH, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, or CKD, in adult patients. Vadadustat is under regulatory review for the treatment of anemia due to CKD in Europe, where it has received a positive opinion from the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, in adult patients on dialysis. Vadadustat is also under regulatory review for the treatment of anemia due to CKD in Australia, Korea, Taiwan and other countries. We continue to pursue a path to potentially gain approval for vadadustat in the U.S. Further, we have several lifecycle management and indication expansion opportunities currently under evaluation or in development for vadadustat.

•HIF-PH inhibitors in preclinical development. The discovery of hypoxia-inducible factor, or HIF, laid the foundation to explore the central role of oxygen sensing in many diseases. As we have seen through the development of vadadustat as a treatment for anemia due to CKD, when stabilized, HIF triggers wide-ranging adaptive, protective responses during hypoxic or ischemic conditions. Our clinical team and research scientists are eager to further develop HIF-PH inhibitors for various indications including acute kidney injury, or AKI, and retinopathy of prematurity, or ROP.

•Maximize the Value of Auryxia: We continue to use our nephrology-focused commercial organization to increase awareness, demand for and adoption of Auryxia for its approved indications with key stakeholders including nephrologists, third-party payors, dialysis organizations and patients.

•Support Vadadustat Globally: We believe vadadustat as a treatment for anemia due to CKD represents a significant opportunity to drive shareholder value. We own full rights to vadadustat in Europe, China, Latin America and certain other territories and U.S. rights subject to our license agreement with CSL Vifor. We received a positive opinion from the CHMP for vadadustat for adult DD-CKD patients, and anticipate that the EC will grant marketing authorization for Vafseo in May 2023. In addition, we are engaged with regulatory bodies in the United Kingdom, Switzerland and Australia, which are part of the ACCESS Consortium, that could lead to approval of vadadustat in these countries. We continue to pursue a path for potential approval for vadadustat as a treatment for anemia in adult DD-CKD patients in the U.S. and remain actively engaged in a process to dispute the CRL issued for vadadustat. We believe in the benefits vadadustat can deliver to patients, if approved.

•Invest in Pipeline and Explore Strategic Growth: We aim to thoughtfully invest in our pipeline by developing internal assets and exploring other strategic growth opportunities.

◦Advance vadadustat clinical development for additional therapeutic indications: We intend to advance development of vadadustat for the treatment of ARDS. We intend to work with UTHealth on an adequate, well-controlled study in a broad patient population, beyond COVID related ARDS.

◦Continue to drive our internal pipeline and portfolio of novel therapeutics. We aim to continue to add to our pipeline and portfolio of novel therapeutics through internal research, discovery and development. We plan to continue to develop early-stage assets and explore opportunities that align with our strategic vision. As a leader in HIF biology, we have invested resources to build out a preclinical portfolio of several potential development candidates which may enter the clinic in the next few years. Areas of interest for pursuit of clinical development include AKI, ARDS and ROP.

1.Anemia due to CKD: results from inadequate levels of EPO, a protein hormone synthesized by specialized cells in the kidney that stimulates red blood cell, or RBC, production in the bone marrow. As renal function declines, the body progressively loses the ability to produce endogenous EPO; and

2.IDA: results from low levels of iron due to abnormal iron absorption and utilization in patients with CKD.

In addition, other agents are in development, including OPKO Health Inc.’s Alpharen™ Tablets (fermagate tablets) and Unicycive’s Renazorb (lanthanum dioxycarbonate) or could otherwise enter the market, including Ardelyx, Inc.’s tenapanor (which is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation, and for which the FDA granted an appeal in the fourth quarter of 2022 that will allow Ardelyx to resubmit a new drug application in 2023 with respect to the control of serum phosphorus in adult patients with CKD on dialysis), that may impact the market for Auryxia.

Auryxia, as an oral drug, is covered by Medicare only under Part D. We have gained access for Auryxia in the United States in both Medicare Part D and commercial channels. Auryxia is currently covered for the Hyperphosphatemia Indication in nine of the ten largest Medicare Part D plans, which provide coverage for approximately 35.8 million people, and the ten largest commercial plans and pharmacy benefit managers in the United States, which provide coverage for approximately 131.0 million people. In September 2018, the Centers for Medicare & Medicaid Services, or CMS, decided that Auryxia would no longer be covered by Medicare for the IDA Indication. While this decision does not impact CMS coverage of the Hyperphosphatemia Indication, it requires all Auryxia prescriptions for Medicare patients to undergo a prior authorization to ensure their use in the Hyperphosphatemia Indication. While we believe that the vast majority of the Medicare prescriptions written for Auryxia today are for the Hyperphosphatemia Indication and therefore will continue to be covered by Medicare with prior authorization, the CMS Decision has had and will continue to have an adverse impact on the sales of Auryxia for the Hyperphosphatemia Indication and the IDA Indication.

Both the INNO2VATE and PRO2TECT Phase 3 programs were global, multicenter, open-label, sponsor-blind, active-controlled non-inferiority programs. In both programs, patients were randomized 1:1 to receive either oral vadadustat or injectable darbepoetin alfa. The primary efficacy endpoint for each study in the INNO2VATE and PRO2TECT programs was the mean change in hemoglobin between baseline and the primary evaluation period. Non-inferiority, or NI, for the primary efficacy endpoint was achieved if the lower bound of the 95% confidence interval for the between-group difference of the mean hemoglobin change did not fall below the pre-specified NI margin. Both the INNO2VATE and PRO2TECT programs included the primary safety endpoint of the assessment of MACE, with a comparison of vadadustat to darbepoetin alfa. MACE is defined as the composite endpoint of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke. The primary safety analysis for each program was based on the combined MACE events from the two studies in each of INNO2VATE and PRO2TECT. NI for the primary safety analysis was achieved if the upper bound of the 95% confidence interval for the hazard ratio of vadadustat to darbepoetin alfa did not exceed the pre-specified NI margin. We prospectively defined and agreed to non-inferiority margins with the United States and European regulatory authorities and agreed with the United States regulatory authorities on the key components of our statistical analysis plan.

The two INNO2VATE studies (Correction/Conversion and Conversion), which collectively enrolled 3,923 patients, evaluated the efficacy and safety of vadadustat versus darbepoetin alfa for the treatment of anemia due to CKD in DD-CKD adult patients.

In INNO2VATE’s Correction/Conversion study of incident dialysis patients (n=369):

•Primary Efficacy Endpoint Result: Vadadustat was non-inferior to darbepoetin alfa. The least square mean difference in Hb was -0.31 g/dL (95% CI: -0.53, -0.10), achieving the pre-specified non-inferiority criterion of -0.75 g/dL. The mean (SD) Hb level at week 24 to week 36 was 10.36 (1.13) g/dL for vadadustat-treated patients compared to 10.61 (0.94) g/dL for darbepoetin alfa-treated patients.

In INNO2VATE’s Conversion study of prevalent dialysis patients (n=3,554):

•Primary Efficacy Endpoint Result: Vadadustat was non-inferior to darbepoetin alfa. The least square mean difference in Hb was -0.17 g/dL (95% CI: -0.23, -0.10), achieving the pre-specified non-inferiority criterion of -0.75 g/dL. The mean (SD) Hb level at week 24 to week 36 was 10.36 (1.01) g/dL for vadadustat-treated patients compared to 10.53 (0.96) g/dL for darbepoetin alfa-treated patients.

•Key Secondary Efficacy Endpoint Result: Vadadustat sustained efficacy in the Conversion study demonstrating non-inferiority to darbepoetin with a least square mean difference in Hb of -0.18 g/dL (95% CI: -0.25, -0.12). The mean (SD) Hb level at week 40 to week 52 was 10.40 (1.04) g/dL in the vadadustat-treated patients compared to 10.58 (0.98) g/dL for darbepoetin treated patients.

The INNO2VATE program (Correction/Conversion and Conversion studies) of dialysis patients (n=3,902):

•Vadadustat was non-inferior to darbepoetin alfa. The upper bound of the 95% confidence interval (CI) of the Hazard Ratio (HR) was below the pre-specified non-inferiority margin of 1.25 for primary MACE analysis (HR 0.96, 95% CI: 0.83, 1.11.).

The incidence of treatment emergent adverse events during the Correction/Conversion study in vadadustat treated patients was 83.8% and 85.5 % in darbepoetin alfa treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa treated patients were hypertension (16.2%/ 12.9%) and diarrhea (10.1%/ 9.7%). Serious treatment emergent adverse events were lower in vadadustat treated patients at 49.7% compared to 56.5% for darbepoetin alfa treated patients. The incidence of treatment emergent adverse events during the Conversion study in the vadadustat treated patients was 88.3%, and 89.3% in darbepoetin alfa treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa treated patients were diarrhea (13.0%/ 10.1%), pneumonia (11.0%/ 9.7%), hypertension (10.6%/ 13.8%), and hyperkalemia (9.0%/ 10.8%). Serious treatment emergent adverse events were slightly lower for vadadustat treated patients at 55.0% and 58.3% for darbepoetin alfa-treated patients. Patients with DD-CKD experienced an increased risk of thromboembolic events compared to darbepoetin alfa with a time to first event HR of 1.20 (95% CI 0.96 - 1.50) driven by thrombosis of vascular access.

The two PRO2TECT studies (Correction and Conversion), which collectively enrolled 3,476 patients, evaluated the efficacy and safety of vadadustat for the treatment of anemia due to CKD in NDD-CKD adult patients.

In PRO2TECT's Correction study (n=1,751):

•Primary Efficacy Endpoint Result: Vadadustat was non-inferior to darbepoetin alfa. The least square mean difference in Hb was 0.05 g/dL (95% CI: -0.04, 0.15), achieving the pre-specified NI criterion of -0.75 g/dL. The mean (SD) Hb level at week 24 to week 36 was 10.39 (0.99) g/dL for vadadustat-treated patients compared to 10.35 (1.03) g/dL for darbepoetin alfa-treated patients.

In PRO2TECT's Conversion study (n=1,725):

•Primary Efficacy Endpoint Result: Vadadustat was non-inferior to darbepoetin alfa. The least square mean difference in Hb was -0.01 g/dL (95% CI: -0.09, 0.07), achieving the pre-specified NI criterion of -0.75 g/dL. The mean (SD) Hb level at week 24 to week 36 was 10.77 (0.98) g/dL for vadadustat-treated patients compared to 10.77 (0.99) g/dL for darbepoetin alfa-treated patients.

•Key Secondary Efficacy Endpoint Result: Vadadustat sustained efficacy in the Conversion study demonstrating non-inferiority to darbepoetin with a least square mean difference in Hb of 0.00 g/dL (95% CI: -0.10, 0.09). The mean (SD) Hb level at week 40 to week 52 was 10.80 (1.04) g/dL in the vadadustat-treated patients compared to 10.79 (1.05) g/dL for darbepoetin alpha-treated patients.

The PRO2TECT program (Correction and Conversion studies) (n=3,471):

The incidence of treatment emergent adverse events during the Correction study in the vadadustat-treated patients was 90.9%, and 91.6% in darbepoetin alfa-treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa-treated patients were end-stage renal disease (34.7%/ 35.2%), hypertension (17.7%/ 22.1.%), hyperkalemia (12.3.%/ 15.6%), urinary tract infection (12.9%/ 12.0%), diarrhea (13.9%/ 10.0%), peripheral oedema (12.5%/ 10.5%), fall (9.6%/ 10%) and nausea (10%/ 8.2%). Serious treatment emergent adverse events were 65.3% for vadadustat-treated patients and 64.5% for darbepoetin alfa-treated patients. The incidence of treatment emergent adverse events during the Conversion study in vadadustat treated patients was 89.1% and 87.7% in darbepoetin alfa-treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa-treated patients were end-stage renal disease (27.5%/ 28.4%), hypertension (14.4%/ 14.8%), urinary tract infection (12.2%/ 14.5%), diarrhea (13.8.%/ 8.8.%), peripheral oedema (9.9%/ 10.1%) and pneumonia (10.0%/ 9.7%). Serious treatment emergent adverse events were 58.5% for vadadustat-treated patients and 56.6% for darbepoetin alfa-treated patients.

During the conduct of our Phase 3 program our team and hepatic experts analyzed hepatic cases (unblinded to treatment) and, following the completion of our global Phase 3 clinical program for vadadustat, there was a review of hepatic safety across the vadadustat clinical program, which included eight completed Phase 2 and 3 studies in NDD-CKD patients, 10 completed Phase 1, 2, and 3 studies, and two then-ongoing Phase 3b studies in DD-CKD patients, and 18 completed studies in healthy subjects (17 Phase 1 and one Phase 3). This review consisted of a blinded re-assessment of hepatic events conducted by a separate panel of hepatic experts. While hepatocellular injury attributed to vadadustat was reported in less than 1% of patients, there was one case of severe hepatocellular injury with jaundice, and we cannot guarantee that similar events will not happen in the future. Additionally, the FDA expressed safety concerns related to the risk of drug-induced liver injury in the CRL that it issued in March 2022.

We and MTPC agreed that, instead of including Japanese patients in our global Phase 3 program for vadadustat, MTPC would be the sponsor of a Phase 3 program for vadadustat in Japan. MTPC reported top-line data for the two Phase 3 pivotal trials and data from the two supportive Phase 3 studies in March 2019 and 52-week data for the two Phase 3 pivotal trials in November 2019. In June 2020, vadadustat was approved in Japan for the treatment of anemia due to CKD by the Ministry of Health, Labor and Welfare. In August 2020, MTPC launched vadadustat commercially in Japan under the trade name, VafseoTM, as a treatment of anemia due to CKD for adult patients on dialysis and not on dialysis. MTPC filed a new drug application for vadadustat for the treatment of anemia due to CKD in adult patients in Taiwan in January 2022 and in Korea in March 2022.

Furthermore, Auryxia’s commercial opportunities may be reduced or eliminated if our competitors develop and market products that are less expensive, more effective, safer or offer greater patient convenience than Auryxia. Other companies have product candidates in various stages of preclinical or clinical development to treat diseases and complications of the diseases for which we are marketing Auryxia. In addition, we entered into settlement agreements with each of our ANDA filers pursuant to which we granted licenses to market a generic version of Auryxia in the United States beginning in March 2025 (subject to FDA approval), or earlier under certain circumstances customary for settlement agreements of this nature, which may impact our business and results of operation.

•completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s good laboratory practice, or GLP, regulations and consistent with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, or ICH, requirements;

•design of a clinical protocol and submission to the FDA of an IND, which must be reviewed and active by the FDA before human clinical trials may begin;

•approval by an independent local or central institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;

•performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed product candidate for each indication;

•preparation and submission to the FDA of an NDA requesting marketing for one or more proposed indications;

•review of the product candidate by an FDA advisory committee, where appropriate or if applicable;

•satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product candidate, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product candidate’s identity, strength, quality and purity;

•satisfactory completion of FDA audits of clinical trial sites and records to assure compliance with GCPs and good practices, or GxPs, the integrity of the clinical data and that adequate controls and oversight are in place regarding manufacturing, clinical trials, pharmacovigilance, safety, data management, vendor oversight, collection and reporting of serious adverse events and other activities;

•payment of user fees and securing FDA approval of an NDA; and

•compliance with any post-approval requirements and/or commitments, including the potential requirement to implement a risk evaluation and mitigation strategy, or REMS, and potentially post-market requirement, or PMR, and post-market commitment, or PMC, studies.

Before a sponsor begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture’s Animal Welfare Act, if applicable. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND and are generally referred to as IND-enabling studies. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted.

Under the Public Health Service Act, or PHSA, sponsors of certain clinical trials of certain FDA-regulated products, including prescription drugs and biologics, are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. The NIH’s Final Rule on registration and reporting requirements for clinical trials became effective in 2017, and both NIH and the FDA have signaled the government’s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors.

Specifically, the PHSA grants the Secretary of the U.S. Department of Health and Human Services, or HHS, the authority to issue a notice of noncompliance to a responsible party for failure to submit clinical trial information as required. The responsible party, however, is allowed 30 days to correct the noncompliance and submit the required information. The failure to submit clinical trial information to clinicaltrials.gov, as required, is also a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. In addition to civil monetary penalties, violations may also result in other regulatory action, such as injunction and/or criminal prosecution or disqualification from federal grants. Although the FDA has historically not enforced these reporting requirements due to HHS’s long delay in issuing final implementing regulations, those regulations have now been issued and the FDA has issued several Notices of Noncompliance to manufacturers since April 2021.

•Phase 1. The product candidate is initially introduced into a small number of healthy human patients or, in certain indications such as cancer, patients with the target disease or condition (e.g., cancer) and tested for

safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.

•Phase 2. The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance and optimal dosage.

•Phase 3. These clinical trials are commonly referred to as “pivotal” studies, which denote a study that presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a product candidate. The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product candidate for approval, identify adverse effects, establish the overall risk-benefit profile of the product candidate and to provide adequate information for the labeling of the product candidate.

•Phase 4. Post-approval studies may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.

The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. Pursuant to the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, the FDA must send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. FDASIA further requires the FDA to publicly post the PREA Non-Compliance letter and sponsor’s response. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.

The FDA conducts a preliminary review of all applications within 60 days of receipt and must inform the sponsor at that time or before whether an application is sufficiently complete to permit substantive review. This is known as the filing decision. In the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File determination to the sponsor. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to certain performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for “priority review” products are meant to be reviewed within six months of filing. A product that has been designated as a breakthrough therapy may also be eligible for review within six months if supported by clinical data at the time of submission of the NDA. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission.

Second, in 2012, Congress enacted the Food and Drug Administration Safety and Improvement Act. This law established a new regulatory scheme allowing for expedited review of products designated as “breakthrough therapies.” A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.  

A PRV is a voucher that the FDA issues to a sponsor of a rare pediatric disease or tropical disease product application at the time of the marketing application approval. Vouchers are transferable to other sponsors that may apply it to their NDAs or BLAs. A PRV entitles the holder to designate a single human drug application submitted under Section 505(b)(1) of the U.S. Federal Food, Drug, and Cosmetic Act or Section 351 of the Public Health Service Act as qualifying for a priority review. An FDA priority review may expedite the review process of a marketing application reducing the review time from ten months after formal acceptance of the file to six months after formal acceptance of the file. Applying the PRV to a marketing application does not ensure the FDA’s approval of the marketing application and all requirements supporting the safety and efficacy of the product must be met. Our NDA submission for vadadustat did not include a PRV.

The FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. The term “substantial evidence” is defined under the FDCA as “evidence consisting of adequate and well-controlled investigations, including clinical

The FDA has interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a new product. Under certain circumstances, however, FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard. This approach was subsequently endorsed by Congress in 1998 with legislation providing, in pertinent part, that “If [FDA] determines, based on relevant science, that data from one adequate and well-controlled clinical investigation and confirmatory evidence (obtained prior to or after such investigation) are sufficient to establish effectiveness, FDA may consider such data and evidence to constitute substantial evidence.” This modification to the law recognized the potential for FDA to find that one adequate and well controlled clinical investigation with confirmatory evidence, including supportive data outside of a controlled trial, is sufficient to establish effectiveness. In December 2019, FDA issued draft guidance further explaining the studies that are needed to establish substantial evidence of effectiveness. It has not yet finalized that guidance.

After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a CRL or an approval letter. To reach this determination, the FDA must determine that the drug is effective and that its expected benefits outweigh its potential risks to patients. This “benefit-risk” assessment is informed by the extensive body of evidence about the product’s safety and efficacy in the NDA or BLA. This assessment is also informed by other factors, including: the severity of the underlying condition and how well patients’ medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks. In connection with this assessment, the FDA review team will assemble all individual reviews and other documents into an “action package,” which becomes the record for FDA review. The review team then issues a recommendation, and a senior FDA official makes a decision.

An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population, indication) described in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product’s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Under the Ensuring Innovation Act, which was signed into law in April 2021, the FDA must publish action packages summarizing its decisions to approve new drugs and biologics within 30 days of approval of such products. To date, CRLs are not publicly available documents.

•restrictions on the marketing or manufacturing of the product, suspension of the approval, or complete withdrawal of the product from the market or product recalls;

•fines, warning letters or holds on post-approval clinical trials;

•refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;

•product seizure or detention, or refusal to permit the import or export of products; or

•injunctions or the imposition of civil or criminal penalties.

Section 505(b)(2) authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the sponsor. NDAs filed under Section 505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the 505(b)(2) sponsor can establish that reliance on the FDA’s previous approval is scientifically appropriate, the sponsor may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) sponsor. Products approved under Section 505(b)(2) are often referred to as follow-on products.

The FDA must establish a priority review track for certain generic drugs, requiring the FDA to review a drug application within eight months for a drug that has three or fewer approved drugs listed in the Orange Book and is no longer protected by any patent or regulatory exclusivities, or is on the FDA’s drug shortage list. The new legislation also authorizes FDA to expedite review of ‘‘competitor generic therapies’’ or drugs with inadequate generic competition, including holding meetings with or providing advice to the drug sponsor prior to submission of the application.

As part of the submission of an NDA or certain supplemental applications, NDA sponsors are required to list with the FDA each patent with claims that cover the sponsor’s product or an approved method of using the product. Upon approval of a new drug, each of the patents listed in the application for the drug is then published in the Orange Book. The FDA’s regulations governing patent listings were largely codified into law with enactment of the Orange Book Modernization Act in January 2021. When an ANDA sponsor files its application with the FDA, the sponsor is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book. Specifically, the ANDA sponsor must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. Moreover, to the extent that the Section 505(b)(2) NDA sponsor is relying on studies conducted for an already approved product, the sponsor also is required to certify to the FDA concerning any patents listed for the NDA-approved product in the Orange Book to the same extent that an ANDA sponsor would.

In April 2014, the Clinical Trials Regulation was adopted. The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the “EU portal”; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.

The Clinical Trials Regulation came into application on January 31, 2022, following confirmation of full functionality of the Clinical Trials Information System through an independent audit by the European Commission in mid-2020. The Clinical Trials Regulation came into application in all the EU Member States and repealed the previous Clinical Trials Directive. According to the transitional provisions, if a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation became applicable, the Clinical Trials Regulation will at that time begin to apply to the clinical trial.

Prior to obtaining a marketing authorization in the EU, sponsors have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate because (a) the product is likely to be ineffective or unsafe in part or all of the pediatric population; (b) the disease or condition occurs only in adult population; or (c) the product does not represent a significant therapeutic benefit over existing treatments for pediatric population. Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.

In particular circumstances, E.U. legislation (Article 14–a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5) and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables sponsors to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the product candidate is intended for the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases; (2) the product candidate is intended to meet unmet medical needs of patients; (3) a marketing authorization may be granted prior to submission of comprehensive clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4) the risk-benefit balance of the product candidate is positive, and (5) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new clinical studies and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization, but sponsors can also request EMA to conduct an accelerated

In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. In addition, third-party payors may impose prior authorization or step edit requirements requiring patients to have tried other therapies prior to our products for coverage. Payors may also decline to include our products or product candidates on their formulary, which means that unless healthcare providers seek a medical exception for coverage, the payors will not pay for the product.

Dialysis organizations have their own formularies that list primary or preferred therapeutic options based on contracting status with drug manufacturers. While a prescriber may make their own independent decision to prescribe what they determine most appropriate for a given patient, any non-formulary therapeutic options are only available through an exception process based on clinical need. Similar to how payor coverage may affect the sales of a product, formulary status within dialysis organizations may affect what products are prescribed within that specific organization. Therefore, if a product is not on a formulary, the prescribers within that organization may be less likely to prescribe that product or may have a difficult time prescribing that product, resulting in less sales. Further, one dialysis organization’s determination to add a product to their formulary does not assure that other dialysis organizations will also add the product to theirs. There is always a risk a dialysis organization will not contract with a drug manufacturer for a specific product, resulting in that product not being on that organization’s formulary. Additionally, dialysis organizations typically assess a product’s efficacy before adding it to their formulary. Their process for assessing a product may differ among organizations and the timing of such assessment could delay adding such treatment to formulary, further affecting product sales.

•the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;

•the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to be made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government

•HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

•the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;

•the U.S. Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment;

•the federal transparency requirements, known as the federal Physician Payments Sunshine Act (renamed the Open Payments Act), under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare & Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;

•the PDMA and its implementation regulations, as well as the DSCSA, which regulate the distribution and tracing of prescription drugs and prescription drug samples at the federal level, and set minimum standards for the regulation of drug distributors by the states; and

•analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by third-party payors, including private insurers, and state gift ban and disclosure law requirements that differ from the federal Physician Payments Sunshine Act in terms of the nature and type of transfers of value that are reportable and the types of covered recipients.

Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, such as Medicare and Medicaid. Ensuring compliance is time consuming and costly. Similar healthcare laws and regulations exist in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information.

In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs. Other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 203. Pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, and subsequent legislation, these Medicare sequester reductions were suspended and reduced through the end of June 2022 but the full 2% cut has resumed as of July 2022. Under current legislation, the actual reductions in Medicare payments may vary up to 4%.

Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the Tax Act, which was signed by the prior administration on December 22, 2017, Congress repealed the “individual mandate.” The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and, on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.

The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, the prior administration issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this

In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would eliminate the current safe harbor drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage Inflation Reduction Act has been delayed by Congress to January 1, 2032.

More recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.

Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.

At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription pharmaceutical and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

In addition, we support kidney patient communities where we live and work. In the United States, we have a patient services program, Akebia Cares, designed to provide one-on-one support to help communicate individual benefits and available resources for patients today facing financial obstacles that keep them from accessing important medications. In 2022, we provided over $5.3 million worth of Auryxia for free to approximately 14,000 patients needing assistance. We also support and work closely with multiple kidney patient advocacy organizations, including the National Kidney Foundation, the American Kidney Fund, the Renal Support Network, Dialysis Patient Citizens and American Association of Kidney Patients. We believe our involvement with these organizations shows our commitment to our purpose of bettering the life of each person impacted by kidney disease.

In March 2022, we received a complete response letter, or CRL, from the FDA regarding our NDA for vadadustat, our lead investigational product candidate, for the treatment of anemia associated with CKD. The FDA concluded that the data in the NDA do not support a favorable benefit-risk assessment of vadadustat for dialysis and non-dialysis patients. In October 2022, we submitted a Formal Dispute Resolution Request, or FDRR, to the FDA. The FDRR focuses on the favorable balance between the benefits and risks of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis in light of safety concerns expressed by the FDA in the CRL for dialysis patients related to the rate of adjudicated thromboembolic events driven by vascular access thrombosis for vadadustat compared to the active comparator and the risk of drug-induced liver injury. In February 2023, we received a second interim response from the FDA to our FDRR, and there can be no assurances that we will be successful in our appeal and obtain approval for vadadustat in a timely manner, on favorable terms, or at all. As a result, the regulatory approval process for vadadustat in the U.S. is highly uncertain. We may not obtain approval at all, and if we are able to obtain approval, the expense and time to do so could adversely impact our ability to successfully commercialize vadadustat or conduct our other business operations, and our financial condition could be materially harmed.

•establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate supplies of products that are compliant with good manufacturing practices, or GMPs, to support the clinical development and the market demand for Auryxia, vadadustat, if approved, and any other product and product candidate, including those that may be in-licensed or acquired;

•current and future restrictions or limitations on our approved or future indications and patient populations or other adverse regulatory actions or in the event that the FDA requires Risk Evaluation and Mitigation Strategies, or REMS, or risk management plans that use restrictive risk minimization strategies;

Our ability to achieve profitability also depends on our ability to manage our expenses. Following receipt of the CRL, in April and May 2022, we implemented a reduction of our workforce, by approximately 42% across all areas of the Company (47% inclusive of the closing of the majority of open positions), including several members of management. In November 2022, we also implemented a reduction of our workforce, by approximately 14% consisting of individuals within our commercial organization as a result of our decision to shift to a strategic account management focused model for our commercial efforts. We recorded a restructuring charge of $15.9 million in the aggregate primarily related to contractual termination benefits including severance, non-cash stock-based compensation expense, healthcare and related benefits in the year ended December 31, 2022. However, we may incur additional costs not currently contemplated due to events associated with or resulting from the workforce reductions. Additionally, the reductions in workforce could impact our operations, including our commercialization of Auryxia, which could affect our ability to generate revenue.

Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency, or the EMA, or other regulatory authorities, or if we otherwise believe it is necessary, to change our manufacturing processes or assays, to amend or replace our study protocols, to conduct any additional clinical trials, whether in order to obtain approval or as a post-approval study, including any additional clinical trial that we decide to conduct for vadadustat, to perform studies in addition to, different from or larger than those currently planned, if there are any delays in completing our clinical trials or if there are further delays in or issues with obtaining marketing approval for vadadustat in the United States, the European Union, or EU, or other jurisdictions. In addition, our ability to generate revenue would be negatively affected if the size of our addressable patient population is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we sought or the patient population for treatment is narrowed by competition, physician choice, coverage or reimbursement, or payor or treatment guidelines. Even though we generate product revenue from Auryxia and royalties from RionaTM and VafseoTM in Japan and may generate revenue and royalties from the sale of any products that may be approved in the future, including those that may be in-licensed or acquired, we may never generate revenue and royalties that are significant enough for us to become and remain profitable, and we will need to obtain additional funding to continue to fund our operating plan beyond Auryxia and certain development activities, and achieve strategic growth.

As of December 31, 2022, our cash and cash equivalents were $90.5 million. We expect to continue to expend substantial amounts of cash for the foreseeable future as we continue to commercialize Auryxia; pursue our appeal for vadadustat in the U.S. with the FDA; support the regulatory process with respect to vadadustat with the EMA and ACCESS Consortium; and develop and commercialize any other product or product candidate, including those that may be in-licensed or acquired. These expenditures will include costs associated with research and development, manufacturing, potentially obtaining marketing approvals and marketing products approved for sale. In addition, other unanticipated costs may arise. Because the outcomes of our current and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of funding necessary to successfully complete clinical development for any current or future product candidates, including vadadustat depending on what is required to address the issues identified in the CRL for vadadustat, including the outcome of our appeal and if additional clinical trials are required in order to obtain marketing approval, or to complete post-marketing studies for Auryxia and vadadustat, if approved. Our future capital requirements depend on many factors, including:

•the scope, progress, results and costs of conducting clinical trials or any post-marketing requirements or any other clinical trials for Auryxia, vadadustat and any other product or product candidate, including those that may be in-licensed or acquired;

We will need to obtain substantial additional funding to fund our operating plan beyond Auryxia and certain development activities, and achieve strategic growth. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

We expect our cash resources to fund our current operating plan through at least the next twelve months from the filing of this Annual Report on Form 10-K. However, if our operating performance deteriorates significantly from the levels achieved in 2022, it could have an effect on our liquidity and our ability to continue as a going concern in the future. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves numerous risks and uncertainties, and actual results could vary as a result of a number of factors, many of which are outside our control. We have based this estimate on assumptions that may be substantially different than actual results, and we could utilize our available capital resources sooner than we currently expect. In addition, if we fail to satisfy any of the covenants under our Loan Agreement with Pharmakon, including the covenant that our Annual Report on Form 10-K for the fiscal year ending December 31, 2023 not be qualified as to going concern, and the loan is accelerated, we may not have sufficient resources to fund our operating plan through the next twelve months. There can be no assurance that the current operating plan will be achieved in the time frame anticipated by us, or that our cash resources will fund our operating plan for the period anticipated by us, or that additional funding will be available on terms acceptable to us, or at all.

Any additional fundraising efforts may divert our management’s attention away from their day-to-day activities, which may adversely affect our ability to develop and commercialize Auryxia and any other products or product candidates, including those that may be in-licensed or acquired, or to continue to seek regulatory approval for vadadustat. Also, additional funds may not be available to us in sufficient amounts or on acceptable terms or at all. If we are unable to raise additional capital in sufficient amounts when needed or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development and/or commercialization of Auryxia and any other products or product candidates, including those that may be in-licensed or acquired, or to take any actions with respect to vadadustat depending on future decisions with respect to vadadustat in the U.S. Any of these events could significantly harm our business, financial condition and prospects.

We may not be successful in our efforts to identify, acquire, in-license, discover, develop and commercialize additional products or product candidates or our decisions to prioritize the development of certain product candidates over others may not be successful, which could impair our ability to grow.

Accordingly, there can be no assurance that we will ever be able to identify, acquire, in-license or develop suitable additional products or product candidates, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential products, product candidates or other programs that ultimately prove to be unsuccessful.

As part of our business strategy, we may engage in additional strategic transactions to expand and diversify our portfolio, including through the merger, acquisition or in-license of assets, businesses, or rights to products, product candidates or technologies or through strategic alliances or collaborations, similar to the Merger and our existing and prior collaboration and license arrangements. We may not identify suitable strategic transactions, or complete such transactions in a timely manner, on favorable terms, on a cost-effective basis, or at all. Moreover, we may devote resources to potential opportunities that are never completed or we may incorrectly judge the value or worth of such opportunities. Even if we successfully execute a strategic transaction, we may not be able to realize the anticipated benefits of such transaction and may experience losses related to our investments in such transactions. Integration of an acquired company or assets into our existing business may not be successful and may disrupt ongoing operations, require the hiring of additional personnel and the implementation and integration of additional internal systems and infrastructure, and require management resources that would otherwise focus on developing our existing business. Even if we are able to achieve the long-term benefits of a strategic transaction, our expenses and short-term costs may increase materially and adversely affect our liquidity. Any of the foregoing could have a detrimental effect on our business, results of operations and financial condition. For example, on June 4, 2021, we entered into a license agreement, the Cyclerion Agreement, with Cyclerion Therapeutics Inc., or Cyclerion, pursuant to which Cyclerion granted us an exclusive global license under certain intellectual property rights to research, develop and commercialize praliciguat, an investigational oral soluble guanylate cyclase, or sGC, stimulator. Although we have progressed preclinical studies for praliciguat, we need to do additional work to manufacture product for clinical trials before we can initiate the trials, and when started, we may be unsuccessful in developing praliciguat. If any of the assumptions that we made in valuing the transaction, including the costs or timing of development of, or the potential benefits of, praliciguat, were incorrect, we may not recognize the anticipated benefits of the transaction and our business could be harmed.

In addition, the direct and indirect impacts of the pandemic or the response efforts to the pandemic, including, among others, competition for labor and resources and increases in labor, sourcing, manufacturing and shipping costs, may cause disruptions to, closures of or other impacts on our CMOs and other vendors in our supply chain on which we rely for the supply of our products and product candidates. For example, areas of China have recently continued to implement lockdowns for COVID-19, which could impact the global supply chain. At this time, our CMOs continue to operate at or near normal levels. However, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our contract manufacturers’ ability to manufacture and deliver Auryxia and vadadustat (if approved in the United States or EMA and which is currently marketed under the trade name VafseoTM by MTPC in Japan), which may result in increased costs and delays, or disruptions to the manufacturing and supply of our products. These impacts could have a negative effect on our inventory reserves, which could result in an increase in inventory write-offs due to expiry.

Our business is substantially dependent on the commercial success of Auryxia. If we are unable to continue to successfully commercialize Auryxia, our results or operations and financial condition will be materially harmed.

Our business and our ability to generate product revenue largely depend on our, and our collaborators’, ability to successfully commercialize Auryxia. Our ability to generate revenue depends on our ability to execute on our commercialization plans, and the size of the market for, and the level of market acceptance of, Auryxia and any other product or product candidate, including those that may be in-licensed or acquired. If the size of any market for which a product or product candidate is approved decreases or is smaller than we anticipate, our revenue and results of operations could be materially adversely affected. For example, the phosphate binder market has declined since 2020, which we believe was partially a result of the COVID-19 pandemic. If the phosphate market does not recover or continues to decline, our revenue from Auryxia could be materially adversely affected.

In order to market Auryxia and any other approved product, we intend to continue to invest in sales and marketing, which will require substantial effort and significant management and financial resources. We have built a commercial infrastructure and sales force in the United States for Auryxia, our only commercial product. However, following receipt of the CRL, in April and May 2022, we implemented a reduction of our workforce by approximately 42% across all areas of the Company (47% inclusive of the closing of the majority of open positions), including several members of management. In November 2022, we also implemented a reduction of our workforce, by approximately 14% consisting of individuals within our commercial organization as a result of our decision to shift to a strategic account management focused model for our commercial efforts. If the remaining sales and marketing team cannot successfully commercialize Auryxia, or if additional sales and marketing employees decide to leave as a result of the reduction in workforce or otherwise, it could have a material adverse effect on Auryxia revenue and our financial condition.

If we obtain regulatory approval to market vadadustat in the U.S., we believe that we can leverage the current commercial foundation for vadadustat in the U.S., but if we are unable to do so successfully this would materially harm our business. Additionally, training a sales force to successfully sell and market a new commercial product is expensive and time-consuming

regarding the Vifor Second Amended Agreement. If vadadustat is approved and we are not able to maintain the Vifor Second Amended Agreement or enter into a supply agreement with DaVita or other dialysis clinics, our business may be materially harmed.

Similar to how payor coverage may affect the sales of a product, formulary status within dialysis organizations may affect what products are prescribed within that specific organization. Therefore, if a product is not on a formulary, the prescribers within that organization may be less likely to prescribe that product or may have a difficult time prescribing that product, resulting in less sales. Further, one dialysis organization’s determination to add a product to their formulary does not assure that other dialysis organizations will also add the product to theirs. There is always a risk a dialysis organization will not contract with a drug manufacturer for a specific product, resulting in that product not being on that organization’s formulary. If any dialysis organization does not add vadadustat, if approved, to the formulary, our business may be materially harmed.

Auryxia is competing in the hyperphosphatemia market in the United States with other FDA-approved phosphate binders such as Renagel® (sevelamer hydrochloride) and Renvela® (sevelamer carbonate), both marketed by Sanofi, PhosLo® and Phoslyra® (calcium acetate), marketed by Fresenius Medical Care North America, Fosrenol® (lanthanum carbonate), marketed by Shire Pharmaceuticals Group plc, and Velphoro® (sucroferric oxyhydroxide), marketed by Fresenius Medical Care North America, as well as over-the-counter calcium carbonate products such as TUMS® and metal-based options such as aluminum, lanthanum and magnesium. Most of the phosphate binders listed above are now also available in generic forms. In addition, other agents are in development, including OPKO Health Inc.’s Alpharen™ Tablets (fermagate tablets) and Unicycive’s Renazorb (lanthanum dioxycarbonate) or could otherwise enter the market, including Ardelyx, Inc.’s tenapanor (which is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation, and for which the FDA granted an appeal in the fourth quarter of 2022 that will allow Ardelyx to resubmit a new drug application in 2023 with respect to the control of serum phosphorus in adult patients with CKD on dialysis), that may impact the market for Auryxia.

product candidates in various stages of preclinical or clinical development to treat diseases and complications of the diseases for which we are marketing Auryxia. In addition, we and Keryx’s licensors, Panion & BF Biotech, Inc., or Panion, and, as applicable, Dr. Hsu, entered into settlement agreements with each of the third parties who submitted Paragraph IV certification notice letters regarding Abbreviated New Drug Applications, or ANDAs, submitted to the FDA, pursuant to which we granted licenses to market a generic version of Auryxia in the United States beginning in March 2025 (subject to FDA approval), or earlier under certain circumstances customary for settlement agreements of this nature, which may impact our business and results of operation.

The commercialization of RionaTM and VafseoTM in Japan and our current and potential future efforts with respect to the development and commercialization of our products and product candidates outside of the United States subject us to a variety of risks associated with international operations, which could materially adversely affect our business.

In addition, we receive revenues from royalty payments converted to U.S. dollars based on net sales of Riona and VafseoTM in Japanese yen. The exchange rates between the Japanese yen on the one hand, and the U.S. dollar, on the other hand, have changed substantially in recent years and may fluctuate substantially in the future. Our results of operations could be adversely affected over time by certain movements in exchange rates, particularly if the Japanese yen depreciates against the U.S. dollar.

We may be unable to successfully complete clinical trials of Auryxia, vadadustat and other product candidates or to successfully obtain approval of vadadustat or other product candidates, if the results of those trials and studies are not positive or are only modestly positive, or if there are concerns with the profile due to efficacy or safety. Further, the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, interim results of a clinical trial do not necessarily predict final results, and results of Phase 3 clinical trials for one indication may not be predictive of results of Phase 3 clinical trials for another indication. For example, we announced positive top-line results from INNO2VATE and vadadustat achieved the primary and key secondary efficacy endpoint in each of the two PRO2TECT studies, but the PRO2TECT program did not meet the primary major adverse cardiovascular event, or MACE, safety endpoint. Many companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we may face similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, in March 2022, we received the CRL for vadadustat indicating that the FDA had determined that it could not approve the NDA in its present form, thus delaying any potential approval of vadadustat. In October 2022, we submitted the FDRR to the FDA and in February 2023, we received a second interim response from the FDA to our FDRR. However, it is impossible to predict when or if vadadustat or any of our other product candidates will prove effective or safe in humans or will receive marketing approval or on what terms. In February 2023, the Committee for Medicinal Products for Human Use, or CHMP, of the EMA adopted a positive opinion recommending the European Commission, or EC, to approve Vafseo™ (vadadustat), an oral HIF-PH inhibitor for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance dialysis. However, before we can market and sell vadadustat in Europe, the EC must approve vadadustat, and there can be no assurances that we will receive such approval in a timely manner, or at all.

Conducting clinical trials outside of the United States, as we have done historically and as we may decide to do in the future, presents additional risks and complexities and, if we decide to conduct a clinical trial outside of the United States in the future, we may not complete such trials successfully, in a timely manner, or at all, which could affect our ability to obtain regulatory approvals.

Data obtained from studies conducted in the United States may not be accepted by the EMA, the PMDA and other regulatory authorities outside of the United States. Also, certain jurisdictions require data from studies conducted in their country in order to obtain approval in that country. Further, when a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, and seeking and receiving informed consent from subjects. Thus, to the extent that we rely on data from foreign clinical studies that are not the subject of an IND but are used to support of an NDA, there is a risk that FDA may not review such data in connection with its review of the NDA.

Undesirable effects caused by, or other undesirable properties of, Auryxia, vadadustat or any other product or product candidate, including those that may be in-licensed or acquired, or competing commercial products or product candidates in development that utilize a common mechanism of action could cause us or regulatory authorities to interrupt, delay or halt clinical trials, could result in a more restrictive label or the delay, denial or withdrawal of marketing approval by the FDA or other regulatory authorities, and could lead to potential product liability claims. In addition, results of our clinical trials could reveal a high frequency of undesirable effects or unexpected characteristics. For example, in March 2022, we received the CRL from the FDA for our NDA for vadadustat in which the FDA concluded that the data in the NDA do not support a favorable benefit-risk assessment of vadadustat for dialysis and non-dialysis patients. The FDA expressed safety concerns noting failure to meet non-inferiority in MACE in the non-dialysis patient population, the increased risk of thromboembolic events, driven by vascular access thrombosis in dialysis patients, and the risk of drug-induced liver injury. In October 2022, we submitted the FDRR to the FDA. The FDRR focuses on the favorable balance between the benefits and risks of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis in light of safety concerns expressed by the FDA in the CRL for dialysis patients related to the rate of adjudicated thromboembolic events driven by vascular access thrombosis for vadadustat compared to the active comparator and the risk of drug-induced liver injury. In February 2023, we received a second interim response from the FDA to our FDRR, and there can be no assurances that we will be successful in our appeal. If we are unable to overcome these concerns, vadadustat may not be approved by the FDA on favorable terms, or at all, and our financial condition could be materially harmed. In February 2023, the CHMP of the EMA adopted a positive opinion recommending the EC to approve Vafseo™ for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance dialysis. However, before we can market and sell vadadustat in Europe, the EC must approve vadadustat, and there can be no assurances that we will receive such approval in a timely manner, or at all.

With respect to the global INNO2VATE Phase 3 program, the incidence of treatment emergent adverse events during the Correction and Conversion study in vadadustat treated patients was 83.8% and 85.5% in darbepoetin alfa treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa treated patients were hypertension (16.2%/ 12.9%) and diarrhea (10.1%/ 9.7%). Serious treatment emergent adverse events were lower in vadadustat treated patients at 49.7% compared to 56.5% for darbepoetin alfa treated patients. The incidence of treatment emergent adverse events during the prevalent dialysis patient study (Conversion) in the vadadustat treated patients was 88.3%, and 89.3% in darbepoetin alfa treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa treated patients were diarrhea (13.0%/ 10.1%), pneumonia (11.0%/ 9.7%), hypertension (10.6%/ 13.8%), and hyperkalemia (9.0%/ 10.8%). Serious treatment emergent adverse events were slightly lower for vadadustat treated patients at 55.0% and 58.3% for darbepoetin alfa-treated patients. Patients with DD-CKD experienced an increased risk of thromboembolic events compared to darbepoetin alfa with a time to first event HR of 1.20 (95% CI 0.96 - 1.50) driven by thrombosis of vascular access.

In March 2022, we received the CRL from the FDA regarding our NDA for vadadustat for the treatment of anemia due to CKD. The FDA concluded that the data in the NDA do not support a favorable benefit-risk assessment of vadadustat for dialysis and non-dialysis patients. In October 2022, we submitted a Formal Dispute Resolution Request, or FDRR, to the FDA. The FDRR focuses on the favorable balance between the benefits and risks of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis in light of safety concerns expressed by the FDA in the CRL for dialysis patients related to the rate of adjudicated thromboembolic events driven by vascular access thrombosis for vadadustat compared to the active comparator and the risk of drug-induced liver injury. In February 2023, we received a second interim response from the FDA to our FDRR, and there can be no assurances that we will be successful in our appeal and obtain approval for vadadustat in a timely manner, on favorable terms, or at all. As a result, the regulatory approval process for vadadustat in the U.S. is highly uncertain. We may not obtain approval at all, and if we are able to obtain approval, it may only be for patients with DD-CKD and, in any event, the expense and time to do so could adversely impact our ability to successfully commercialize vadadustat, and our financial condition could be materially harmed.

seek regulatory approval in the UK and/or the EU for vadadustat or any other product candidate, which could significantly and materially harm our business. As of January 1, 2021, the Medicines and Healthcare Products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended) as the basis for regulating medicines.

•the relevant regulatory authority may disagree with our interpretation of data from our preclinical studies and clinical trials;

•the relevant regulatory authority may require that we conduct additional clinical trials or repeat one or more clinical trials;

•the relevant regulatory authority may grant approval contingent on the performance of costly post-marketing clinical trials;

•we or our third party manufacturers may fail to perform in accordance with the FDA’s or other relevant regulatory authority's cGMP requirements and guidance;

•the relevant regulatory authority could deem that our financial relationships with certain principal investigators constitute a conflict of interest, such that the data from those principal investigators may not be used to support our applications;

•as part of any future regulatory process, the FDA may ask an Advisory Committee to review portions of the NDA, the FDA may have difficulty scheduling an Advisory Committee meeting in a timely manner or, if convened, an FDA Advisory Committee could recommend non-approval, conditions of approval or restrictions on approval, and the FDA may ultimately agree with the recommendations;

Marketing approvals may be subject to limitations on the approved indicated uses for which the product may be marketed or other conditions of approval, or contain requirements or commitments for potentially costly post-marketing studies and surveillance to monitor the safety and efficacy of the product, including REMS, or registries or observational studies. For example, in connection with the FDA approvals of Auryxia, we initially committed to the FDA to conduct certain post-approval pediatric studies of Auryxia under the Pediatric Research Equity Act of 2003, or PREA. With regard to the Hyperphosphatemia Indication for Auryxia, we committed to completing the post-approval pediatric study and submitting a final report to the FDA by December 31, 2019. However, we did not complete the study and therefore did not submit the post-marketing requirement pediatric clinical study report by December 31, 2019. Consequently, we received a notification of noncompliance with PREA. Our request to extend this deadline was denied, and the study is considered delayed although we have initiated sites in the study and are recruiting for one patient cohort. Recruitment of the other patients is pending receipt of further data regarding the manufacturing of the smaller size tablets and the FDA’s concurrence before proceeding with the use of such formulation. With regard to our IDA Indication, we initially committed to completing the post-approval pediatric study and submitting a final report to the FDA by January 2023. We did not meet a milestone relating to this post-approval pediatric study of Auryxia in a timely manner and received a notification from the FDA. Subsequently, the FDA agreed to extend the pediatric clinical study timelines for the IDA Indication. We subsequently communicated to the FDA that we would be delaying the start of the clinical trial in the IDA Indication while we work to produce smaller size tablets. In response, the FDA issued a partial clinical hold until we manufacture the smaller tablets and provide the FDA with relevant information regarding the smaller sized tablets for review. The FDA lifted the partial clinical hold in June 2022, however, we have not commenced start up of this study pending resolution of the manufacturing of the smaller size tablets. If we are unable to complete these studies successfully, or have further delays in completing these studies, we will need to inform the FDA, have further discussions and, if the FDA finds that we failed to comply with pediatric study requirements, in violation of applicable law, it could institute enforcement proceedings to seize or enjoin the sale of Auryxia or seek civil penalties, which would have a material adverse impact on our ability to commercialize Auryxia and our ability to generate revenues from Auryxia.

For example, we previously had three limited, voluntary recalls of Auryxia. These and any other recalls or any supply, quality or manufacturing issues in the future could result in significant negative consequences, including reputational harm, loss of customer confidence, and a negative impact on our financials, any of which could have a material adverse effect on our business and results of operations, and may impact our ability to supply Auryxia, VafseoTM, in Japan or vadadustat, if approved, for commercial and clinical use.

•the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;

•HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

•HIPAA, as amended by the HITECH, and their respective implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

•analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws and gift ban and transparency statutes, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by state Medicaid or other programs, or non-governmental third party payors, including private insurers, and which are not preempted by federal laws and often differ from state to state, thus complicating compliance efforts; and

•U.S. state laws restricting interactions with healthcare providers and other members of the healthcare community or requiring pharmaceutical manufacturers to implement certain compliance standards, which vary from state to state.

The ability of the FDA and regulatory authorities outside the U.S. to review and approve new products can be affected by a variety of factors, including global health concerns, government budget and funding levels, staffing shortages, statutory, regulatory, and policy changes and other events that may otherwise affect the FDA’s or other regulatory authorities' ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result of certain of these factors. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may increase the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our

Legislative and regulatory healthcare reform may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain for any products that are approved in the United States or foreign jurisdictions.

More recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.

Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.

We depend on collaborations with third parties for the development and commercialization of Auryxia, Riona, Vafseo and vadadustat and if these collaborations are not successful or if our collaborators terminate their agreements with us, we may not be able to capitalize on the market potential of Auryxia, Riona, Vafseo and vadadustat, and our business could be materially harmed.

We sublicensed the rights to commercialize Riona to JT and Torii in Japan. We also entered into a collaboration agreement with MTPC to develop and commercialize vadadustat in Japan and certain other Asian countries. In addition, we entered into the Vifor Second Amended Agreement pursuant to which we granted CSL Vifor an exclusive license to sell vadadustat to the Supply Group in the United States. We also granted to Averoa an exclusive license to develop and commercialize ferric citrate

We also rely upon third parties to store and distribute drug product for our clinical trials. For example, we use third parties to store product at various sites in the United States to distribute to our clinical trial sites. Any performance failure on the part of our storage or distributor partners could delay clinical development, marketing approval or commercialization, resulting in additional costs and depriving us of potential product revenue.

Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and governmental patent agencies in other jurisdictions also require compliance with a number of procedural, documentary, fee payment (such as annuities) and other similar provisions during the patent application process. While an inadvertent lapse in many cases can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market sooner than we expect, which would have a material adverse effect on our business.

The market entry of one or more generic competitors or any third party’s attempt to challenge our intellectual property rights will likely limit Auryxia sales and have an adverse impact on our business and results of operation.

We previously received Paragraph IV certification notice letters regarding ANDAs submitted to the FDA requesting approval for generic versions of Auryxia tablets (210 mg ferric iron per tablet). We filed complaints for patent infringement relating to such ANDAs, and subsequently entered into settlement and license agreements with all such ANDA filers that allow such ANDA filers to market a generic version of Auryxia in the United States beginning on March 20, 2025. It is possible that we may receive Paragraph IV certification notice letters from additional ANDA filers and may not ultimately be successful in an ANDA litigation. For example, in February 2023, we received another Paragraph IV certification notice letter regarding an ANDA submitted to the FDA. Generic competition for Auryxia or any of our potential future products could have a material adverse effect on our sales, results of operations and financial condition.

management. In November 2022, we also implemented a reduction of our workforce, by approximately 14% consisting of individuals within our commercial organization. The reductions in workforce reflect our strategic pillars to drive Auryxia revenue while also continuing to decrease operating costs. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. We recorded a restructuring charge of approximately $15.9 million in the aggregate primarily related to contractual termination benefits including severance, non-cash stock-based compensation expense, healthcare and related benefits in the year ended December 31, 2022. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. We also cannot guarantee that we will not have to undertake additional workforce reductions or restructuring activities in the future, including as a result of the FDA's decision related to our appeal of the CRL for vadadustat. Furthermore, our cost savings plan may be disruptive to our operations, including our commercialization of Auryxia, which could affect our ability to generate product revenue. In addition, our workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, or disruptions in our day-to-day operations. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, manufacturing and sales and marketing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully commercializing Auryxia and from successfully developing and commercializing our product candidates in the future, including vadadustat, if approved. If we are ultimately successful in obtaining approval of vadadustat in the United States, we will need to hire additional employees to support the commercialization of vadadustat in the United States, and if we are unsuccessful or delayed in doing so, the potential launch of vadadustat could be delayed.

In our day-to-day operations, we may encounter difficulties in managing the size of our operations as well as challenges associated with managing our business. We have strategic collaborations for the commercialization of Riona and the development and commercialization of vadadustat, which is now being marketed under the trade name VafseoTM by our collaboration partner, MTPC, in Japan. Additionally, in the United States, we have a strategic relationship with CSL Vifor related to the commercialization of vadadustat, if approved. As our operations continue, we expect that we will need to manage our current relationships and enter into new relationships, especially in light of the termination of our collaboration agreements with Otsuka, with various strategic collaborators, consultants, vendors, suppliers and other third parties. These relationships are complex and create numerous risks as we deal with issues that arise.

Our employees, independent contractors, principal investigators, CROs, CMOs, consultants and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. In addition, laws and regulations governing any international operations we have or may have in the future may require us to develop and implement costly compliance programs.

As a public company, we operate in a demanding regulatory environment, and we have and will continue to incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Capital Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and certain corporate governance practices. In particular, our compliance with Section 404 of the Sarbanes-Oxley Act has required and will continue to require that we incur substantial accounting-related expenses and

expend significant management efforts. Our testing, or the testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls that we would be required to remediate in a timely manner. If we are not able to comply with the requirements of the Sarbanes-Oxley Act, we could be subject to sanctions or investigations by the SEC, the Nasdaq Capital Market or other regulatory authorities, which would require additional financial and management resources and could adversely affect the market price of our securities. Furthermore, if we cannot provide reliable financial reports or prevent fraud, including as a result of remote working by our employees, our business and results of operations would likely be materially and adversely affected.

Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

Our Ninth Amended and Restated Certificate of Incorporation, as amended, or Charter, and our Amended and Restated By-Laws, or Bylaws, as amended to date, contain provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the State of Delaware, or DGCL, the personal liability of our directors and executive officers for monetary damages for breach of their fiduciary duties as a director or officer. Our Charter and our Bylaws also provide that we will indemnify our directors and executive officers and may indemnify our employees and other agents to the fullest extent permitted by the DGCL.

•We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.

Our stock price has been and will likely continue to be volatile. The stock market in general and the market for similarly situated biopharmaceutical companies specifically have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. Since our initial public offering in March 2014, the price of our common stock as reported on The Nasdaq Stock Market has ranged from a low of $0.24 on October 24, 2022 to a high of $31.00 on June 20, 2014. The daily closing market price for our common stock varied between a high price of $2.93 on March 9, 2022 and a low price of $0.25 on November 17, 2022 in the twelve-month period ending on December 31, 2022. During that time, the price of our common stock ranged from an intra-day low of $0.24 per share to an intra-day high of $2.93 per share. The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section,

Sales of substantial amounts of shares of our common stock or other securities by our employees or our other stockholders or by us under our shelf registration statement, pursuant to at-the-market offerings or otherwise, could dilute our stockholders, lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities.

Our corporate headquarters are located in Cambridge, Massachusetts. We currently lease approximately 65,167 square feet of office and lab space in Cambridge, Massachusetts, and 27,300 square feet of office space in Boston, Massachusetts. Excluding renewal options, the lease for our Cambridge, Massachusetts office space expires on September 11, 2026 and the lease for the Cambridge, Massachusetts lab space expires on January 31, 2025. In February 2022 we extended the term of the lease for our Boston, Massachusetts office space, such that the lease expires on July 31, 2031. In September 2019, we entered into an agreement to sublease the Boston office space to Foundation Medicine, Inc., which expired on February 28, 2023. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms for our future growth.